Archive · 31 Oct 2025
Cipla Focuses on Obesity and Chronic Therapies Amidst Revenue Shift
Cipla, a large medicine company, announced how well it did in the last three months (the second part of their financial year).
Their total money earned went up by 8%, reaching over 7,500 crore rupees.
Their profit also grew a little bit.
This good performance comes as Cipla is focusing more on medicines for long-term health issues like diabetes and also for weight loss.
They have partnered with another company, Eli Lilly, to sell a new medicine called Yurpeak, which helps with diabetes and weight.
They have also started selling a generic version of a popular diabetes drug.
Cipla is also working on new medicines in the U.S., including treatments for breathing problems and complex biological drugs.
They are also investing more money in developing new medicines for the future.
Cipla reported an 8% year-on-year revenue growth to ₹7,589 crore for Q2 FY26, with a net profit increase of 3.7% to ₹1,351 crore.
The company achieved a strong EBITDA margin of 25% and is focusing on chronic and obesity therapies, including distributing Yurpeak (Tirzepatide) in partnership with Eli Lilly.
Cipla launched a generic version of Semaglutide in India's anti-diabetes market to bolster its presence in metabolic health.
In the U.S., Cipla's revenue was $233 million, with plans to build its portfolio of complex generics, peptides, and biosimilars as Revlimid sales decrease.
Research and development spending increased to ₹539 crore (7.1% of revenue) for planned launches of respiratory drugs, peptide products, and biosimilars.
- Who
- Cipla Ltd., including remarks from Managing Director and Global CEO Umang Vohra.
- What
- Cipla reported an 8% year-on-year revenue increase to ₹7,589 crore and a 3.7% profit rise to ₹1,351 crore for Q2 FY26, driven by a strategic focus on chronic therapies like diabetes and obesity, including the launch of Yurpeak (Tirzepatide) and a generic Semaglutide. The company is also diversifying its US portfolio as revenue from its key cancer drug Revlimid begins to taper.
- When
- The second quarter of FY26, ended September 30, 2025.
- Where
- Cipla Ltd., a global pharmaceutical company based in Mumbai, with significant operations in India, the U.S., South Africa, and Europe.
- Why
- To maintain steady growth and address market opportunities, particularly in the growing obesity and advanced diabetes care segments, as revenue from established products like Revlimid declines. Diversification into complex generics, peptides, and biosimilars in the U.S. is also a key strategy.
- Company
- Cipla Ltd.
- Reporting Period
- Q2 FY26 (Quarter ended September 30, 2025)
- Q2 Revenue
- ₹7,589 crore
- Revenue Growth (YoY)
- 8%
- Q2 Net Profit
- ₹1,351 crore
- Profit Growth (YoY)
- 3.7%
- EBITDA Margin
- 25%
- R&D Spending
- ₹539 crore (7.1% of revenue)
